https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50584 Wed 28 Feb 2024 15:06:35 AEDT ]]> Side effects and toxicities of targeted therapies in stage IV melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20976 Sat 24 Mar 2018 07:54:20 AEDT ]]>